2′-O-Acetyl RNA Cap Structures for Higher-Yield Polyribonucleotides

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing methods for producing polyribonucleotides with 2′-O-methyl ribose cap structures face challenges in yield and efficiency, limiting their application in RNA therapeutics.

Innovation Solution

The development of polyribonucleotides with a 5′ cap structure comprising a 2′-O-acetyl ribose, which demonstrates similar yields as those with 2′-O-methyl ribose, allowing for the production of polyribonucleotides with modified nucleobases and riboses, including compounds of Formulae I and II, and their use in pharmaceutical compositions.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If 2′-O-methyl ribose cap structure is used for producing polyribonucleotides, then the production yield is limited, but using alternative cap structures may improve yield

Engineering Contradiction:

Improveproduction yieldVSAvoidmanufacturing complexity

Core Design Contradiction:

ProductivityVSEase of manufacture

Solution Approach 1:

The patent changes the chemical parameter of the cap structure from 2′-O-methyl ribose to 2′-O-acetyl ribose, which fundamentally alters the production yield characteristics while maintaining compatibility with existing polyribonucleotide manufacturing processes

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent employs a transient acetyl group in the cap structure that can be easily introduced and removed, facilitating higher yield production without requiring permanent structural changes to the polyribonucleotide molecule

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

2Adaptability or versatility

If polyribonucleotides with modified nucleobases and riboses are produced, then versatility for therapeutic applications is enhanced, but manufacturing complexity increases

Engineering Contradiction:

Improvetherapeutic application versatilityVSAvoidmanufacturing process complexity

Core Design Contradiction:

Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The patent segments the modification strategy by applying different modifications to specific components (nucleobases and riboses) independently, allowing flexible combination of modifications tailored to specific therapeutic applications while managing manufacturing complexity through modular approaches

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent creates a universal cap structure platform (2′-O-acetyl ribose) that can accommodate various modified nucleobases and riboses, enabling a single manufacturing platform to produce multiple therapeutic polyribonucleotide variants with different functionalities

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentUS12559515B2Cap compounds and RNAS comprising the same

Publication Date: 2026.02.24 HELIX NANOTECHNOLOGIES INC

AI summary

Disclosed herein are 5′ cap structures comprising a 2′-O-acetyl ribose. Also provided herein are polyribonucleotides comprising a 5′ cap structure disclosed herein and compositions comprising the same as well as methods of making and using the same.